MRNS logo

Marinus Pharmaceuticals, Inc


MRNS: Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.


Show MRNS Financials

Consumer Interest
SEC Filings

Recent trades of MRNS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by MRNS's directors and management

Government lobbying spending instances

  • $40,000 Apr 22, 2010 Issue: Defense
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard

Number of mentions of MRNS in WallStreetBets Daily Discussion


Recent insights relating to MRNS

CNBC Recommendations

Recent picks made for MRNS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MRNS

Corporate Flights

Flights by private jets registered to MRNS